Chronic Rhinosinusitis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You must be at least 18 years old when you sign the consent form
- You must be able to understand and agree to take part in the study by signing a consent form
- You must have a condition called chronic rhinosinusitis with nasal polyps (a long-term sinus condition where growths develop inside the nose)
- You must meet the qualifying requirements set by your country or health system to be prescribed a specific type of medication called a "biologic" (such as omalizumab, mepolizumab, or dupilumab)
Who may not be able to join:
- You may not be able to join if you have been treated with a different biologic medication within the 3 months before starting your current biologic treatment (note: this rule does not apply if you are already in the trial and are switching from one biologic to another)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Peter Hellings, MD,PhD, Universitaire Ziekenhuizen KU Leuven
Phone: 003216342037
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To evaluate the effect of biologicals (omalizumab, mepolizumab and dupilumab) on the nasal congestion score (NCS).
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.